Nimotuzumab, a humanized anti-epidermal development aspect receptor monoclonal antibody, was presented with at a dosage of 200 mg weekly for 6 cycles. node dissection Rabbit Polyclonal to CES2 had been performed 5C6 weeks following the conclusion of neoadjuvant therapy. Outcomes Twenty-eight patients had been enrolled. Clinical comprehensive response and incomplete response were within 8 (28.5%) […]